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Abstract
Background: Low back pain is common and a significant number of patients experience chronic low back pain.
Current treatment options offer small to moderate effects. Patients with vertebral bone marrow lesions visualized as
Modic changes on magnetic resonance imaging may represent a subgroup within the low back pain population.
There is evidence for inflammatory mediators being involved in development of Modic changes; hence, suppression of
inflammation could be a treatment strategy for these patients. This study examines the effect of anti-inflammatory
treatment with the TNF-α inhibitor infliximab in patients with chronic low back pain and Modic changes.
Methods/design: The BackToBasic trial is a multicenter, double blind, randomized controlled trial conducted at six
hospitals in Norway, comparing intravenous infusions with infliximab with placebo. One hundred twenty-six patients
aged 18–65 with chronic low back pain and type 1 Modic changes will be recruited from secondary care outpatients’
clinics. The primary outcome is back pain-specific disability at day 154 (5months). The study is designed to detect a
difference in change of 10 (SD 18) in the Oswestry Disability Index at day 154/ 5 months. The study also aims to refine
MRI-assessment, investigate safety and cost-effectiveness and explore the underlying biological mechanisms of Modic
changes.
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Discussion: Finding treatments that target underlying mechanisms could pose new treatment options for patients
with low back pain. Suppression of inflammation could be a treatment strategy for patients with low back pain and
Modic changes. This paper presents the design of the BackToBasic study, where we will assess the effect of an anti-
inflammatory treatment versus placebo in patients with chronic low back pain and type 1 Modic changes.
The study is registered at ClinicalTrials.gov under the identifier NCT03704363. The EudraCT Number: 2017–004861-29.
Keywords: Low back pain, Modic changes, Inflammation, Clinical trial, TNF- α inhibitor, Infliximab, Randomized
controlled trial
Background
Low back pain (LBP) is the leading cause of disability
worldwide [1]. The condition is very common, affecting
all age groups and the costs for patients and society are
immense [2]. About 10% of patients with LBP develop
chronic LBP (cLBP). The vast majority of patients (80–
90%) are classified as having non-specific LBP, [3] and
treatment focus on reducing symptoms [4]. Unfortunately,
these treatment options offer only small to moderate ef-
fects [2]. Researchers therefore attempt to identify sub-
groups within the non-specific LBP group that are likely
to respond favorably to specific treatment [5, 6]. Patients
with vertebral bone marrow lesions visualized as Modic
changes (MCs) on magnetic resonance imaging (MRI)
have been suggested to represent such a subgroup [7].
MCs are defined as type 1, 2 and 3 based on T1- and T2
weighted MRI [8, 9]. Type 1 (oedema type) is hypo-intense
on T1- and hyper-intense on T2- weighted MRI, type 2
(fatty type) is hyper-intense on T1- and T2- weighted MRI,
and type 3 (sclerotic type) is hypo-intense on T1- and T2-
weighted MRI. Combined types are common. MC types
can change over time, and the different types are thought
to reflect a common underlying process [8, 10].
Several studies have reported a possible association be-
tween cLBP and MCs [11]. The association is not consistent,
[12] but possibly more evident for type 1 than type 2 MCs
[13–15]. Despite clinical experience that MCs can be painful;
the etiology is unknown, though an infectious, mechanical,
or autoimmune pathogenesis is hypothesized [16–20]. A Da-
nish randomized controlled trial (RCT) from 2013 reported
that 100 days of antibiotic treatment was substantially more
effective than placebo in patients with LBP and type 1 MCs
[21]. These results were not confirmed in a recently pub-
lished Norwegian RCT [22]. The diverging results under-
score the need for further research to understand the
underlying causes and significance of MCs.
The autoimmune theory suggests that MCs are second-
ary to a biomechanical degradation that causes a subse-
quent autoimmune response [7]. Animal models have
shown that nucleus pulposus cells are immunogenic and
may trigger an inflammatory cascade resulting in MCs
[20]. Independent of what the true etiology of MCs is,
there is evidence for inflammatory mediators being in-
volved in painful disc degeneration and MCs [7, 23]. TNF-
α is a pleiotropic pro-inflammatory cytokine that is found
to be expressed in MCs, along with IL-1 β, IL-6 and IL-8
[24]. Also, Othori et al. found significantly more TNF-
immunoreactive cells in MCs compared with patients
without MCs [25]. Clinical trials suppressing the inflam-
matory response by giving steroid injections or TNF-α in-
hibitors in patients with acute LBP and sciatica have been
conducted [26–29]. In the Korhonen study, a subgroup
with concomitant MCs had a possible beneficial effect of
TNF-α inhibitors [29]. Thus, suppression of inflammation
emerges as a possible treatment strategy for patients with
cLBP and MCs.
This article details the protocol of the BackToBasic
study, which aims to assess the effect of treatment with
the TNF-α inhibitor infliximab on disease-specific dis-
ability in patients with cLBP and type 1 MCs.
The study will also explore underlying biological
mechanisms of MCs by studying potential biomarkers,
investigate the gut microbiome, genetic susceptibility
and epigenetics, evaluate cost-effectiveness, and refine
MRI assessment for cLBP with MCs.
Methods
Overview of study design
The BackToBasic study is a multicenter, randomized,
placebo-controlled, double-blind phase III trial of inflixi-
mab in patients with cLBP and type 1 MCs. The sched-
ule for enrolment, interventions and assessments are
given in Table 1.
Study population and recruitment
The flow of patients in the BackToBasic study is illus-
trated in Fig. 1. We plan to include and randomize 126 pa-
tients with cLBP and type 1 MCs. The first patient was
included December 2018. Patients referred to secondary
care outpatient clinics due to cLBP are screened for eligi-
bility at the six participating hospitals in all health regions
in Norway. (Oslo University Hospital, Ullevål; Haukeland
University Hospital, Bergen; St. Olavs Hospital,
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Trondheim; University Hospital of North Norway,
Tromsø; Østfold Hospital Trust, Moss; Vestre Viken
Hospital trust, Drammen). Recruiting clinicians screen
eligible patients for inclusion and exclusion criteria,
and refer for a standardized study-specific baseline
1.5 T MRI examination to confirm and characterize
the MCs. The MRI scans are de-identified and inde-
pendently evaluated by two study radiologists.
To be included in the trial participants must fulfill the
following inclusion criteria:























Urine pregnancy testb X X X X X
Blood samples (hematology, clinical
chemistry, CRP)c
X X X X X X
TB, Hep C, Hep B-screening X
Allocation X
INTERVENTION:
Infliximab X X X X
Placebo X X X X
ASSESSMENTS:
Background datad X X
Clinical safety evaluatione X X X X X X
Clinical pain/neuro evaluationf X
Blood samples for drug concentrations and
antibodiesg
X X X X X
Blood samples for biobank X X X
Adverse events X X X X X
Primary outcomeh X X X X X
Pain monitoringi X X X X X X
Concomitant medication X X X X X X X
Co-interventions (non-pharm) X X X X X X X
Sick listing X X X X
Questionnairesj X X X
Compliancek X X X X
aBaseline MRI according to the study protocol can be maximum 4weeks old when treatment starts. A follow-up MRI is taken between 6 and 7months after
treatment start (i.e. 7 to 8 months after baseline MRI).
bUrine pregnancy test will be performed at screening and monthly from treatment initiation until 9 months. Results will be enquired with telephone follow up.
cHaematological parameters (hemoglobin, haematocrit (hct), erythrocytes, white blood cells with differentials, platelet counts), Clinical chemistry (AST and/or ALT,
ALP, albumine, creatinine, random glucose, potassium, sodium) and CRP (SLV-imposed). Random glucose is for further safety monitoring (self-imposed)
dBaseline data
eWeight, blood pressure, pulse, auscultation of hearth and lunges, GI and neurological examination
fPain provocation tests, neurological tests
gAntibodies to infliximab
hODI
iPain-monitoring (LBP intensity) weekly during follow-up period
jEQ 5D-5L,RMDQ, Patients’satisfaction, global perceived effect, symptom specific well-being, leg pain intensity, hours with LBP last 4 weeks
kNumber of completed intravenous infusions with the IMP
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 Age between 18 and 65 years
 LBP of > 50% of days for > 6 months duration in the
area below the 12th rib and above the gluteal folds
with a Numerical Rating Scale (NRS) pain intensity
score of ≥ 5 (mean of three 0–10 NRS scales: current
LBP, the worst LBP within the last 2 weeks, and the
usual/mean LBP within the last 2 weeks) and/or
Oswestry Disability Index (ODI-score) ≥25
 MC of craniocaudal size ≥10% of vertebral height and of
primary or secondary type 1 in the vertebral body at a level
of the lumbar spine (superior or inferior endplate, Th12-S1)
 Negative pregnancy test
 Signed informed consent obtained and documented
according to ICH GCP, and national/local regulations
The patients will be excluded if there is a specific diag-
nosis that may explain their low back symptoms (e.g.
tumour, fracture, spondyloarthritis, infection, spinal
stenosis), former low back surgery (L1 – S1) for other
reasons than disc herniation or decompression, and also
if surgery for disc herniation or decompression has been
carried out within the last 12 months prior to inclusion.
Fig. 1 Flow-chart of the BackToBasic trial
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Patients who regularly use opioids with the exception of
codeine and tramadol are not eligible. Further exclusion
criteria include infections, pregnancy, diabetes, immuno-
deficiency or the use of immunosuppressive medication.
A full list of exclusion criteria is provided in Table 2.
Data registration and monitoring
The web-based eCRF software solution, Viedoc™,
(Pharma Consulting Group, Uppsala, Sweden) is used to
collect study data. The Principal Investigator at each
study center is responsible for assuring that data entered
into the eCRF are complete, accurate and entered in a
timely manner. The electronic signature of the investiga-
tor will attest the accuracy of the data in each eCRF. If
any assessments are omitted, the reason will be noted on
the eCRFs. Corrections will be recorded giving their rea-
son. A complete list of authorized study personnel will
be maintained during the study, and only authorized
study personnel will be allowed to sign the eCRF. Proto-
col, protocol amendments, investigator’s brochure and
all study-related documents have been reviewed by an
institutional review board and a Good Clinical Practice
(GCP) medical monitor. All participating centers will be
monitored during and after the trial in order to ensure
compliance with GCP, the protocol and all other applic-
able regulations. The monitoring is conducted by the
Clinical Trial Unit, Oslo University Hospital; Clinical Re-
search Department, St. Olavs Hospital, Trondheim;
Centre for Quality Improvement and Development, Re-
search and Innovation, Research & Development, Hau-
keland University Hospital; Clinical Research
Department, Centre for Quality Improvement and De-
velopment, University Hospital of North Norway,
Data collection
Data will be collected and entered in Viedoc™ at screening,
baseline, during the treatment period and at day 154 /5
months and day 278/9months after the first treatment, re-
gardless of patients’ compliance to the study protocol, follow-
ing the Recommendations for Interventional Trials (SPIRIT).
During the trial, patients fill in patient reported outcome
measures (PROMs) via ViedocMe (eCRF). Table 3 shows
the full set of PROMs and time schedule. Patients enter
data via a smartphone, tablet or PC using a personal user-
name and password. If the forms are not filled out in time,
they will receive two automatically generated SMS or
email-reminders. For participants unable to use the Vie-
docMe eCRF, a paper version will be available, and study
personnel will transfer the data into the eCRF.
The following background data will be collected at base-
line; age, gender, BMI, ethnicity, marital status, children,
educational level, work status, physical work load, leisure
time activity, smoking habits, medical history, expectations
about treatment effect and characteristics of pain (duration,
aggravating factors, morning stiffness, morning pain, relief
by NSAIDs, night time pain and former treatment). Emo-
tional distress will be measured using the Hopkins Symp-
tom Checklist-25 [30], fear-avoidance beliefs about physical
activity and work with Fear-avoidance beliefs Questionnaire
(FABQ) [31]. Subjective health complaints (SHC) will be
assessed using a formal inventory that consists of 29 ques-
tions concerning severity and duration of subjective somatic
and psychological symptoms [32].
At the screening visit a clinical examination including
pain provocation tests (springing test, active flexion / ex-
tension of the lumbar spine) and neurological tests
(strength, toe−/heel walking, sensibility, reflexes, straight
leg raising test, reverse Lasegue test)) is performed.
Co-interventions and concomitant medication will be
registered at all visits.
Randomization and blinding
Included patients are allocated in a 1:1 ratio between active
treatment and placebo, using a computer randomization
procedure stratified by center and previous participation in
the Norwegian AIM study [22]. The randomization is
blocked within each stratum. Details of block size and allo-
cation sequence generation are provided in a separate
document that is unavailable to those who enroll patients
or give the treatment. Treatment allocation is performed
using the Viedoc™ application. Patients, investigators, treat-
ment administrators, data analyst and statistician are
blinded to the treatment allocation. The only unblinded
personnel at each site will be the mixing nurse and the con-
troller, who prepares the infusions for treatment adminis-
tration and control that the correct amount and substance
is used. These will have no contact with patients, investiga-
tors or treatment administrators other than handing them
the prepared infusion bags. Each study site has a site-
specific, detailed procedure to ensure blinding during the
entire study period. Each site is carefully assessed to ensure
that blinding procedures are strictly followed.
Un-blinding of the treatment allocation is only permissible
if the safety and well-being of the patient is being compro-
mised. The decision to reveal the treatment allocation during
the study may only be done by the principal investigator.
Trial interventions and schedule
For this study biosimilar infliximab and NaCl used as pla-
cebo are defined as Investigational Medicinal Products
(IMP). The test treatment is 5 mg/kg infliximab. Both
drugs are administered as intravenous infusions. The infu-
sion bags containing the study medication will be pre-
pared by the mixing nurse in identical infusion bags, and
applied labels with patient number and dose such that
blinding of the participants is secured. The IMPs have the
same color and will look the same. After preparing the
IMP, the mixing nurse will hand over the IMP to a study
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nurse, who is blinded to allocation, and authorized by the
local principal investigator to administer the infusion. The
trial treatment will be given at day 0, 14, 42 and 98, unless
unacceptable side effects are encountered. No dose adjust-
ments will be done. All patients take premedication with
1 g of paracetamol and 10mg of cetirizine prior to each
infusion. NaCl is the comparator as there is no proven
highly effective pharmacological treatment for cLBP and
type 1 MCs [33].
Patients will not receive one particular standard of
care prior to inclusion or during the trail. They are
allowed to continue their regular LBP therapy, but
are encouraged not to start new treatments during
the treatment and follow-up period. If a patient
needs new treatment during the trial this will be re-
corded, and the difference in additional therapies be-
tween the placebo and intervention group may be
assessed.
Table 2 Full list of exclusion criteria
Exclusion criteria:
• Fever or ongoing infection
• Allergy or hypersensitivity against any products of the medication
• Previous infliximab treatment
• Any serious adverse events with other immunosuppressive treatment (including cytostatics, antibodies, drugs acting on immunophilins, Interferons,
mycophenolate and any other DMARDs)
• Any specific diagnosis that may explain patient’s low back symptoms (e.g. tumour, fracture, spondyloarthritis, infection, spinal stenosis).
• Former low back surgery (L1 – S1) for other reasons than disc herniation or decompression (e.g. fusion, disc prosthesis).
• Former surgery for disc herniation or decompression within the last 12 months
• Any known rheumatic disease
• Current pregnancy or lactation
• For women of childbearing potential (WOCBP); inadequate birth control, pregnancy, and/or breastfeeding. WOCBP is defined as those who are
fertile (with uterus, fallopian tubes and at least one intact functional ovary), following menarche and until becoming post-menopausal unless per-
manently sterile. Permanent sterilization methods include hysterectomy, bilateral salpingectomy and bilateral oophorectomy. Documentation of sur-
gical procedure or physical examination is required for subjects who have had such an operation. Adequate contraception must be used by
WOCBP during the entire intervention period and 6months after the last administration of study drug, and includes oral, injected or implanted hor-
monal methods of contraception, placement of an intrauterine device or system, vasectomized partner or sexual abstinence.
• Ongoing systemic glucocorticoid or other immunosuppressive treatments (see list above)
• Regular use of opioids with the exception of codeine and tramadol
• Other immunosuppressive treatment last year (see list above)
• Active or latent (known or suspected) tuberculosis (all participants will be screened for latent tuberculosis)
• Previous infection with Hepatitis B virus (HBV) (all participants will be screened for HBV-carrier state)
• Live vaccination within the last 4 weeks or planned live vaccination during treatment period
• Planned surgical procedure
• Increased transaminases (ASAT/ALAT)
• Ongoing or previous malignant disease at any time (i.e. skin cancer, cervical cancer etc.)
• Known increased risk of malignant disease
• Diabetes
• Immunodeficiency (i.e. primary immunodeficiency diseases, human immunodeficiency virus/acquired immunodeficiency syndrome, splenectomy)
• Heart failure (NYHA class III - IV)
• Previous or ongoing psoriasis
• Ulcerative colitis or Crohns disease
• Existing or recent demyelination diseases (I.e. MS or Guillain-Barres)
• Abnormal hemoglobin or abnormal platelet, leucocyte or neutrophil count
• Not able to understand written and spoken Norwegian
• Not able to complete treatment or follow-ups in the study (i.e. severe psychiatric disease, drug abuse or plans of moving address)
• Contra indications for MRI (i.e. pacemaker, metal implants, claustrophobia)
• Abnormal creatinine level
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There will be an end of study visit at day 154 (5
months); the main end-point, and a telephone follow up
for safety registration at day 278 (9 months).
Outcome measures
See Tables 1 and 3 for time points.
Primary outcome measure
We will use the Norwegian validated version of the
Oswestry Disability Index (ODI) version 2.0 [34, 35].
ODI is a disease-specific disability score recommended
for use in LBP research [36]. ODI gives a summed up
score from 0 (no disability) to 100 (maximum disability)
based on 10 questions.
Secondary outcome measures
 Short tau inversion recovery (STIR) signal (intensity
and extent) of MCs on MRI
Baseline and follow-up MRI of the lumbar spine includes
sagittal T1- and T2-weighted images, axial T2-weighted im-
ages and sagittal STIR, fat-water separation and diffusion
weighted images. Radiologists will evaluate a range of MC
features, including signal intensity and extent.
 Low back pain intensity
Low back pain intensity will be measured as a mean of
three Numeric Rating Scale assessments (NRS: 0–10);
current LBP, the worst LBP within the last 2 weeks, and
usual/mean LBP within the last 2 weeks.
 Roland Morris Disability Questionnaire (RMDQ)
RMDQ is a self-reported disease-specific disability
score, ranging from 0 to 24, higher scores indicate more
disability [34, 35].
 Health-related quality of life
Quality of life will be measured using EuroQoL-5D-5L
(version 2.0), the values are converted to a single utility
index, range− 0.59 to 1.0, worse to better respectively [37].
 Co-interventions
Concomitant pharmacological treatment (ATC-coded)
and non-pharmacological treatment by self-report.
 Days with sick leave
Table 3 Patient reported outcome measures
Outcome measures Timeline
– Oswestry Disability Index (ODI) 2.0, range 0–100 (Primary outcome) Day 0, 28, 56, 91, 120, 154(5 months) and 278 (9
months)
– Low back pain intensity (mean of three Numeric Rating Scales (NRSs, range 0–10); current
LBP, the worst LBP within the last 2 weeks, and usual/mean LBP within the last 2 weeks (for
weekly reports during the intervention period; the wording “last 2 weeks” will be replaced by
“the last week”)
Every week during treatment period and at day
154(5 months) and 278 (9 months)
– Roland and Morris Disability Questionnaire (RMDQ), range 0–24 Day 0, 56, 154(5 months) and 278 (9 months)
– Leg pain intensity (NRSs, range 0–10) last week Day 0, 56, 154(5 months) and 278 (9 months)
– Hours with LBP during the last 4 weeks Day 0, 56, 154(5 months) and 278 (9 months)
– Symptom-specific well-being Day 0, 56, 154(5 months) and 278 (9 months)
– Days with sick leave Day 0, 28, 56, 91, 120, 154(5 months) and 278 (9
months)
– Co-interventions Day 0, 28, 56, 91, 120, 154(5 months) and 278 (9
months)
– Concomitant medication Day 0, 28, 56, 91, 120, 154(5 months) and 278 (9
months)
– Patients’ satisfaction Day 0, 56, 154(5 months) and 278 (9 months)
– Global perceived effect Day 0, 56, 154(5 months) and 278 (9 months)
– EQ. 5D-5L Day 0, 56, 154(5 months) and 278 (9 months)
– Emotional distress (Hopkins Symptom Checklist–25) Reported at baseline
– Fear-avoidance beliefs Questionnaire (FABQ) Reported at baseline
– Subjective health complaints (SHC) Reported at baseline
– Background information Reported at baseline
– Perceived treatment Day 7, 56, 154(5 months) and 278 (9 months)
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Patients report the number of days on sick leave last
month (if patients are sick listed; degree / % sick listed
will also be registered).
 Incidence of adverse events (AEs) and serious
adverse events (SAEs) during the study period
AEs and SAEs are registered continuously during the
whole study period, and we will assess the frequency,
duration and intensity using precise standard medical
terminology. In the evaluation, we will also consider
serum infliximab concentration and vital signs.
Explorative outcome measures
 Leg pain intensity
Patients will be asked to grade the leg pain last week
using NRS (0–10).
 Hours with low back pain
Number of days during the last 28 days (4 weeks) the
participant had experienced LBP (0–28 days), and, on a
typical day, how many hours awake they experienced
LBP (0–16 h). The number of days and hours are multi-
plied (a 0–448 scale).
 Symptom-specific well-being
Measured on a 5-point Likert scale with ‘very satisfied’,
‘some satisfied’, ‘neither satisfied nor dissatisfied’, ‘some
dissatisfied’ or ‘very dissatisfied’ [38, 39].
 Patients’ satisfaction
Rated on a 5-point Likert scale; patient’s rate satisfac-
tion with treatment.
 Global perceived effect from baseline
Global Rating of Change is rated on a 7-point Likert scale
to quantify a patient’s self-judged improvement from baseline.
 Perceived treatment
Patients are asked which study medicine (Infliximab /
placebo / unsure) they think they received during the
intervention period, and to what extent infliximab will
have an effect on their low back pain.
Laboratory tests
Hematology, clinical chemistry and acute phase reac-
tants are recorded at all visits. Local laboratories will do
the analyses. Serum samples for measurement of infliximab
concentrations and anti-drug antibodies will be drawn from
all participants at all visits except at screening. All samples
will be analyzed at the Department of Medical Biochemistry
at Oslo University Hospital, Radiumhospitalet, using in
house assays automated on the AutoDELFIA (PerkinElmer,
Waltham, MA) immunoassay platform. Results will be re-
corded in the laboratory data system and transferred to the
PI upon the conclusion of the trial. In case of an emergency,
serum infliximab and anti-drug levels can be reported to cli-
nicians upon request. Biological samples will be collected
and stored in a certified biobank freezer at − 80 °C. The bio-
bank samples will be used for research purposes only, includ-
ing genetic variation, epigenetics, gene- and protein
expression and biomarkers.
Furthermore, patients are asked to collect fecal samples at
baseline, 14weeks and 22weeks. The patients will receive
equipment for collecting fecal samples at home, using Stool
Collection Tubes with Stool DNA Stabilizer. The material
will be analyzed by sequencing bacterial genome.
Adverse events and safety
Safety is monitored by the assessment of physical exam-
ination and laboratory tests, including hematology, mea-
sures of liver and kidney function, and recording adverse
events at every visit. Women in childbearing age will
take a pregnancy test every month. Each patient is
instructed to contact the investigator immediately
should they develop symptoms they perceive as serious.
The investigators report all adverse events (AEs) in the
eCRF at each visit during the treatment period, post
treatment and at safety registration at 9 months. Serious
adverse events (SAEs) must be reported to the medical
monitor within 24 h after the study site has gained
knowledge of the SAE. Any suspected unexpected and
serious adverse reaction (SUSAR) will be reported to the
Competent Authority according to national regulation.
AEs are described in precise medical terminology by the
investigator, as well as duration, intensity, attribution,
action taken and outcome of the adverse event. A data
manager at the Clinical Trial Unit, Oslo University Hos-
pital, will code the AEs and SAEs using the Medical Dic-
tionary for Regulatory Activities (MedDRA.)
The medical monitor keeps detailed records of all SAEs
reported by the investigators and performs an evaluation
with respect to causality and expectedness.
Statistical methods and data analysis
The primary objective for this trial is to determine if
infliximab improves ODI score from baseline to day 154
(5 months) in patients with cLBP and type 1 MCs, com-
pared to placebo. The null hypothesis is that there is no
difference between active treatment and placebo. The al-
ternative hypothesis is that a difference exists.
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Determination of sample size
The sample size estimation for this study is based on the
following assumptions:
 Two-sided test with a 5% significance level
 Power: 80%
 Treatment allocation ratio: 1:1
 Clinically important difference in improvement
between groups: 10 ODI points.
 Standard deviation of difference between 154 days/5
months and baseline of 18 ODI points.
With these assumptions, a total sample size of 104 is
required (using Stata 16.0 command power twomeans).
We added 20% to allow for dropouts, resulting in a total
sample size of 126 patients, 63 in each treatment.
Data analysis
The following populations will be considered for the
analyses:
 Intention to treat population: All randomized
participants, regardless of protocol adherence
 Full analysis set: All randomized patients who have
taken at least one dose of study medication.
 Safety population: All randomized patients who have
taken at least one dose of study medication, i.e.
identical to the full analysis set.
 Per Protocol set: All randomized patients who
sufficiently comply with the protocol. Criteria for
inclusion in the Per Protocol- population will be
specified in the statistical analysis plan, and the final
criteria will be defined prior to database lock.
Planned analyses
The main statistical analysis is planned when the intended
number of patients has been included and has either final-
ized their last assessment or is/has withdrawn according to
protocol procedures. Also, all data have to be entered, veri-
fied and validated according to the data management plan.
Prior to the statistical analysis, the data base will be
locked for further entering or altering of data. A separate
statistical analysis plan (SAP) will provide further details on
the planned statistical analyses. The SAP will be finalized,
signed and dated prior to database lock and published at
ClinicalTrials.gov. The treatment allocation will be revealed
after the database lock and used in the statistical analysis.
Deviation from the original statistical plan will be de-
scribed and justified in the reporting of the study. Amend-
ments to the plan can be done until day of database lock.
The primary analyses of the efficacy endpoints will be
done in the Full analysis set. Sensitivity analyses will be
done in the Per Protocol set.
Primary analyses
 Description of data
Continuous variables will be summarized using stand-
ard summary statistics such as number of observations
(n), mean value, standard deviation (SD), minimum and
maximum value, median value, and 1st and 3rd quar-
tiles. Demographic data and other baseline characteris-
tics will be summarized using descriptive statistics.
 Analysis of Efficacy Data
The primary endpoint is the change in the Oswestry
Disability Index (ODI) from baseline to day 154 (5
months.) A linear mixed model will be fitted to the pri-
mary outcome, including a random intercept and an
interaction term of time and treatment. The model will
be adjusted for baseline ODI score (prior to treatment)
and stratification factors used at randomization. The lin-
ear mixed model is equipped to handle missing data.
Secondary analyses
Continuous secondary outcomes measured over time will
be analyzed in a similar manner as for the primary end-
point. Binary endpoints will be analyzed by logistic regres-
sion models, or mixed logistic models, if appropriate.
Further details will be given in the SAP.
Ethics approval and consent to participate
The BackToBasic study protocol has been approved by the
Regional Committee for Medical Research Ethics in Norway
(REC South East, reference number 2017/2450) and the
Norwegian Medicines Agency (SLV). The study is registered
at ClinicalTrials.gov under the identifier NCT03704363. The
EudraCT Number: 2017–004861-29. Any important proto-
col modifications will be reported to the relevant parties.
All patients will receive oral and written information
and give their written informed consent before screen-
ing. Patients can withdraw their consent at any time.
The patient information and informed consent form has
been approved by the regional ethics committee before
enrolment of patients in the study. The study is con-
ducted in accordance with the Declaration of Helsinki
and with ICH/Good Clinical Practice, and will be re-
ported in accordance with the Consolidated Standards of
Reporting Trials (CONSORT) guidelines [40]. Registra-
tion and storage of patient data are carried out in ac-
cordance with international personal data laws (GDPR).
Trial organization and funding
The BackToBasic study is investigator initiated and inde-
pendent of the pharmaceutical industry. Oslo University
Hospital is sponsor and the Norwegian national program
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for clinical therapy research, KLINBEFORSK, funds the
trial, both are governmental organizations.
Discussion
This paper presents the design for a randomized, double-
blind, placebo-controlled parallel group trial that will as-
sess the effect of infliximab, a TNF-α inhibitor, in patients
with low back pain with concomitant type 1 MCs.
The majority of acute episodes with LBP have a good
prognosis. However, a significant number of patients experi-
ence recurrent episodes or chronic complaints [41, 42].
Current clinical guidelines for non-specific LBP recommend
largely generic, symptomatic treatments such as advice to
stay active and avoid bed-rest, and analgesic medications, re-
assurance and exercises. These existing treatments, however,
have only small to moderate effects [4, 41]. One explanation
for ineffective treatments for non-specific LBP may be that
we are unable to direct treatment towards the underlying
pathology and instead have to rely upon generic treatments
in a heterogeneous patient-population [43].
MCs have been linked to cLBP and suggested as a sub-
group within the cLBP [7]. Whatever the etiology of MCs
is, it seems clear that local inflammatory responses in the
intervertebral disc and vertebral end plates are involved [7,
23]. Data from animal models have shown that nucleus pul-
posus cells from the disc can be immunogenic and trigger
an inflammatory cascade in the vertebra, which results in
MCs [20]. Hence, anti-inflammatory treatment in patients
with cLBP and MCs could offer a novel treatment strategy.
MCs are strongly associated with adjacent disc degener-
ation and end plate damage [7]. Tumor necrosis factor
(TNF)-α is expressed in both symptomatic disc degener-
ation and MCs [24]. TNF-α triggers the expression of IL-
1β, IL-6, and IL-8, and inhibiting TNF by infliximab re-
duces their expression in-vitro [44]. Toll-like receptors
(TLR TLR1/2/4/6) are expressed in degenerated discs,
which can possibly be due to higher TNF levels, driving
an autoimmune response [45, 46]. Ohtori et al. found sig-
nificantly more PGP 9.5-immunoreactive nerve fibres and
TNF-immunoreactive cells in the endplates from patients
with MCs compared to patients without MCs. They also
found more nerve fibres in MC type 1 endplates compared
to MC type 2 endplates [25], and concluded that endplate
abnormalities are related to inflammation and axon
growth induced by TNF. Thus TNF-α could play a central
role in the inflammatory responses linked to MCs. Al-
though the pathogenesis of MCs and their role in cLBP is
not fully understood, inhibiting TNF-α is a potential
treatment-strategy warranting further investigation.
Only patients with type 1 MCs are eligible for this
trial. Part of the rationale for this is the higher number
of TNF immunoreactive cells found in endplates with
type 1 MCs compared to type 2 MCs [25]. Moreover,
type 1 MCs are considered to represent a stage of more
active inflammation, whereas type 2 and 3 could be a
more quiescent stage of the same process [7, 47].
Inhibitors of TNF- α have provided significant treatment ad-
vances in several inflammatory diseases, including axial spon-
dyloarthritis [48, 49]. Patients with ankylosing spondylitis
treated with infliximab show improvement of inflammation
measured by bone marrow edema on STIR sequences [50].
In order to reduce the risk of insufficient dosage, we use the
approved dosing regimen for ankylosing spondylitis, which is
5mg/kg. Serum drug concentration and anti-drug antibody
levels are measured before each infusion. Dosages are not ad-
justed based on serum drug concentration levels, as these are
not made available to investigators or treatment administra-
tors. However, serum drug concentration levels and antibody
levels can be relevant in the evaluation of potential effects and
adverse events, and will be assessed after the trial.
Treatment with infliximab can cause side effects. Inclu-
sion and exclusion criteria have been carefully considered
by the study group to ensure that only the patients where
immune suppressive treatment is considered safe are en-
rolled in the trial. Furthermore, treatment is given by
trained personnel, patients will be observed for 1 h after
the infusions, and participants will be monitored closely
for infections or other possible side effects of treatment.
ODI is an approved outcome measure for use in LBP re-
search, especially for evaluation of treatment effect in patients
from secondary health care. Based on recommendations we
consider a between-group difference of 10 ODI points as clin-
ically relevant, and similar between-group differences have
been used in former trials [51–55]. An important change for a
patient should be greater than the naturally occurring fluctua-
tions in cLBP. We consider a between-group difference of 10
ODI points to be of importance for the patients, given the na-
ture of the intervention and its associated risks.
In the search of new treatment options for patients with
non-specific LBP, there is a need for refined diagnostic as-
sessment to identify possible subgroups that might benefit
from specific interventions. This trial will evaluate a range
of MC-characteristics by MRI. Machine-learning software
will be applied to MRI-data in order to automatically iden-
tify MC-features, and hence improve the assessment of
MCs. Along with the clinical trial we will also explore po-
tential biomarkers, including gene expression and epigen-
etic profiling, to increase our knowledge of underlying
factors of MC-related LBP. A full set of pre-specified hy-
potheses is available in the Appendix (Table 4).
Participant recruitment was initiated December
2018 and is ongoing. Anticipated recruitment period
is 3 years. Upon study completion the results of the
trial will be submitted for publication in a publicly
accessible database of clinical study results. Also the
results will be submitted to the Competent Authority
and the Ethics Committee according to EU and na-
tional regulations.
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Appendix
Table 4 List of pre specified objectives
Objectives Endpoints
Primary Objective A: Primary efficacy endpoint:
To evaluate the effect of biosimilar infliximab on disease specific disability in
patients with chronic low back pain and Modic changes type 1
Oswestry Disability Index change from baseline to day 154 (5
months)
Secondary Objective B: Secondary endpoints:
To evaluate the effect of biosimilar infliximab on bone marrow oedema in
patients with chronic low back pain and Modic changes type 1
– Short tau inversion recovery (STIR) signal (intensity and extent)
of MCs from baseline to 5/6 months
Objective C: Secondary endpoints:
To evaluate the effect of biosimilar infliximab on pain in patients with chronic
low back pain and Modic changes type 1
– LBP intensity at day 154 (5 months) follow-up
Objective D: Secondary endpoints:
To evaluate the effect of biosimilar infliximab on disease specific disability in
patients with chronic low back pain and Modic changes type 1
– Roland Morris Disability Questionnaire at day 154 (5 months)
follow-up
Objective E: Secondary endpoints:
To evaluate whether the short tau inversion recovery (STIR) signal (intensity
and extent) of Modic changes type 1 on baseline MRI predicts clinical outcome
– ODI score at day 154 (5 months) follow-up
– LBP intensity at day 154 (5 months) follow-up
Objective F: Secondary endpoints:
To evaluate the effect of biosimilar infliximab on health-related quality of life in
patients with chronic low back pain and Modic changes type 1
– Health-related quality of life (the EQ-5D) at day 154 (5 months)
follow-up
Objective G: Secondary endpoints:
To evaluate cost-effectiveness of biosimilar infliximab in patients with chronic
low back pain and Modic changes type 1
– ODI score at day 154 (5 months) follow-up
– Health-related quality of life (the EQ-5D) at day 154 (5 months)
follow-up
– Co-interventions (pharm. and non-pharmacological)
– Days with sick-leave
Objective H: –
To evaluate the incidence of AEs and SAEs in patients who receive biosimilar
infliximab
Exploratory To evaluate the effect of biosimilar infliximab versus placebo on other
outcome measures not mentioned above in patients with chronic low back
pain and Modic changes type 1
Exploratory endpoints at day 154 (5 months) follow-up:
– Leg pain intensity
– Hours with LBP during the last 4 weeks
– Symptom-specific well-being
– Days with sick leave
– Co-interventions
– Patients’ satisfaction
– Global perceived effect
To evaluate the long-term effect of biosimilar infliximab versus placebo on pain
and disability in patients with chronic low back pain and Modic changes type
1
Exploratory endpoints:
– ODI at 9 months follow-up
– Leg pain intensity at 9 months follow-up
To evaluate the feasibility of machine learning to assess imaging features of
Modic changes type 1
Exploratory endpoints:
– Machine detected features of MCs baseline and 6months
To investigate the underlying biological mechanisms of Modic changes type 1
through combined gene expression and epigenetic profiling and correlate
with clinical outcome
Exploratory endpoints:
– Epigenetic patterns, longitudinal gene- and protein
expression, genetic variation at baseline, end of treatment and
at 5 months
To identify biomarkers for any TNF-alfa blockers response in patients with
chronic low back pain and Modic changes type 1
Exploratory endpoints:
– Protein expression at baseline
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